Paul O’Connor (University of Toronto) and colleagues reported results of the BEYOND study, evaluating the effectiveness of high and low doses (500 mcg
vs. 250 mcg) of
Betaseron® (interferon beta-1b) and
Copaxone. Participants numbered 899, 892, and 448 in these groups, respectively. No differences were found in the risk of relapse, the primary endpoint, or secondary endpoints such as MRI findings.